Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Coya Therapeutics (NASDAQ:COYA – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Volatility & Risk
Madrigal Pharmaceuticals has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Insider and Institutional Ownership
98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Madrigal Pharmaceuticals | $958.40 million | 11.97 | -$288.28 million | ($12.89) | -38.51 |
| Coya Therapeutics | $8.02 million | 14.19 | -$21.23 million | ($1.07) | -4.53 |
Coya Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Madrigal Pharmaceuticals and Coya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Madrigal Pharmaceuticals | -25.32% | -56.65% | -25.53% |
| Coya Therapeutics | -270.22% | -52.05% | -46.34% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Madrigal Pharmaceuticals and Coya Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Madrigal Pharmaceuticals | 1 | 2 | 15 | 0 | 2.78 |
| Coya Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
Madrigal Pharmaceuticals currently has a consensus price target of $710.20, indicating a potential upside of 43.06%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 216.15%. Given Coya Therapeutics’ higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Madrigal Pharmaceuticals.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About Coya Therapeutics
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
